BICO (Q4 review): Improving outlook and trades at <1x sales - Redeye

BICO’s Q4 report broadly aligned with our estimates, showing slightly negative organic growth and adjusted EBITDA profitability of 12.5%. Performance was supported by a strong quarter in Lab Automation, while Life Science Solutions faced some headwind and tough comps. Despite execution risks inherent to a turnaround, from an EV/S perspective the stock remains conspiciously cheap, trading at <1x 2026e, which is far below medtech peers.

Länk till analysen i sin helhet: https://www.redeye.se/research/1151833/bico-q4-review-improving-outlook-trading-at-ev-s-2026e-1x?utm_source=finwire&utm_medium=RSS